COVID-19 Patients
Conditions
Brief summary
Burden: Initial outbreak of corona virus disease 2019 (COVID-19) was reported from Wuhan, China in early December 2019.Presently known to be caused by a novel beta-corona virus, named as Severe acute respiratory syndrome corona virus 2 ( SARS-CoV-2). World Health Organization (WHO) declared a pandemic on March. The clinical characteristics of COVID-19 include respiratory symptoms, fever, cough, dyspnoea and pneumonia Infected individuals exhibit: 1. Mostly mild illness (80% +) recover without any treatment (\ 80%) 2. Moderate illness that needs hospitalization and recovers after standard 3. supportive treatment (\ 14%) 4. Critical illness (\ 5%) needs ICU support 5. Death (1-2% ) COVID-19 has now spread \>210 countries and territories globally. SARS-CoV-2 is a respiratory virus which spreads primarily through droplets generalized when an infected person coughs or sneezes or through droplets of saliva or discharge from the nose. Symptomatic management remains the mainstay of treatment strategy. Mortality appears to be more common in older individuals and those with co-morbidities, such as chronic lung disease, cardiovascular disease and diabetes. Young people with no comorbidities also appear to be at risk for critical illness including multi-organ failure and death. Seen more in Bangladesh between 21-40 yrs of age. Knowledge Gap: There is no specific treatment against this new virus that WHO has officially declared until now.There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. National Guidelines on Clinical Management of Corona virus Disease 2019 (Covid-19): V 5.0 date 9th April 2020) CDC, DGHS, GoB Thus an RCT is urgently needed in Bangladesh: Based on recent literatures on Rx studies in COVID-19 patients from other countries as well as its availability & affordability of those repurposed medicines
Detailed description
Objectives: General Objective: The aim of the study is to evaluate efficacy and safety of ivermectin in combination with doxycycline or ivermectin alone for the treatment of hospitalized SARS-CoV-2 infected adult Bangladeshi COVID-19 +ve patients and to compare with placebo; where all three arms will receive the standard care of treatment of COVID-19 infected patients in the hospital. By successful demonstration of the safety and efficacy of these repurposed medicines, it may have the potential to play an important role in the treatment of COVID-19+ve patients. Specific Objective: 1. Duration of the virological clearance rate 2. Days required for remission of fever and cough Secondary Objective: * Patients requiring oxygen * Patients failing to maintain SpO2 \>88 despite oxygenation * Number of days on oxygen support * Chest X-ray improvement * Duration of hospitalization * All cause mortality
Interventions
DRUGIvermectin + Doxycycline + Placebo
Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5) Placebo one tablet D2-5
DRUGIvermectin + Placebo
Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
DRUGPlacebo
Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
Sponsors
International Centre for Diarrhoeal Disease Research, Bangladesh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Randomized, Double-Blind, Placebo-Controlled Trial
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criterion: * Bangladeshi aged 18-65 years admitted to any of the aforementioned study sites (hospitals) * Either sex * At the enrollment having at least one of the following symptoms: Temp 37.5 C or above, Cough, Sore throat * SpO2 \>94% * Duration of illness ≤ 7 days * No oxygen support on enrollment * Capable of swallowing oral medication * PCR positive for SARS-CoV2 virus * The participant properly informed about the study and agreed to sign the informed consent form (ICF)
Exclusion criteria
* Allergy to ivermectin or doxycycline; or other contraindications to any of the study medications * History of chronic heart disease (IHD, heart failure, documented cardiomyopathy etc) * History of chronic liver disease (SGPT value more than 3 times of normal value) * History of chronic kidney disease (S. Creatinine for male \>1.3 mg/dL or \>115 µmol/L and for female \>1.2 mg/dL or \>106.1 µmol/L) * Pregnant or lactating women * Participated in any other clinical trial within last 4 weeks * H/o received Ivermectin/Doxycycline within last 7 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Virological clearance | within 7 days after enrollment | • Presence of virus will be negative on Day 7 detected by RT PCR |
| Remission of fever | within 7 days after enrollment | • Body temperature will be \< 37.5 C by day 7 detected by Infrared thermometer |
| Remission of cough | within 7 days after enrollment | • Remission of cough: No signs of cough showing respiratory rate within 12-20/ min, on day7 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of hospitalization | within 14 days after enrollment | Hospital stay ≥7days to ≤14 days as per CRF records |
| Patients requiring oxygen | within 7 days after enrollment | Detected SPO2 level \<94% on Day 7or before by pulse oxymeter |
| All causes of mortality | within 14 days after enrollment | Death any time during 14 days of study period from any cause recorded in CRF and Hospital death certificate |
| Patients failing to maintain SpO2 >93% despite oxygenation | within 7 days after enrollment | Patients who fail to maintain pulse oxymeter detected SpO2 level\>93% despite O2 supplementation of 2-6 L/min, on Day 7 or before |
| Number of days on oxygen support | within 7 days after enrollment | Any number of days on oxygen support on Day 7 or before recorded in CRF |
Countries
Bangladesh
Outcome results
None listed